Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 30, 2022American Journal of HematologyOpen Access

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

View Full Paper
Ask AI
Bookmark
Share

Authors

AZAmer M. ZeidanUBUma BorateDPDaniel A. Pollyea

Discussion

Loading...

Member takes

Overview

Phase 1b trial demonstrates clinical activity and survival benefit with venetoclax and azacitidine in relapsed or refractory myelodysplastic syndromes, indicating a viable option after therapy...

Key Points

  • To evaluate the safety and clinical efficacy of venetoclax combined with azacitidine in patients with relapsed or refractory myelodysplastic syndromes after prior hypomethylating agent failure.
  • Enrolled 44 patients (86% male, median age 74 years) with relapsed or refractory myelodysplastic syndromes to receive venetoclax plus intravenous or subcutaneous azacitidine.
  • Followed patients for a median of 21.2 months and assessed clinical responses according to the modified 2006 International Working Group (IWG) criteria.
  • Complete remission occurred in 7% (n = 3) and marrow complete remission in 32% (n = 14), with a median duration of response of 8.6 months and a median overall survival of 12.6 months.
  • Transfusion independence for red blood cells and/or platelets was achieved by 36% (16/44) of patients, and hematological improvement occurred in 43% (6/14) of those with marrow complete remission.
  • Grade ≥ 3 adverse events included febrile neutropenia (34%), thrombocytopenia (32%), neutropenia (27%), anemia (18%), and pneumonia (23%).

Cite This Study

Zeidan et al. (2022) studied this question.

synapsesocial.com/papers/6a007a7db124fe581985ea39https://doi.org/10.1002/ajh.26771
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes2025 · 1 citations
  2. 2Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study2026
  3. 3Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)2025
  4. 4A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia2024 · 15 citations
  5. 5Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia2024 · 226 citations